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Nearly 1 billion people worldwide are affected by hypertension. Despite current pharmacological approaches to control blood pressure, this condition remains one of the most common causes of heart failure, kidney disease and stroke 1 . Endothelial dysfunction is associated with hypertension, and is an early event contributing to vascular tone dysregulation [2] [3] [4] .
Endothelium-released nitric oxide (NO) is of critical importance for the maintenance of normal blood pressure [5] [6] [7] . Sphingolipids, particularly sphingosine-1-phosphate (S1P), have emerged as a class of bioactive lipids with important functions in cardiovascular homeostasis, including blood pressure control. Acting through G proteincoupled S1P receptors, S1P regulates arterial tone. At low concentrations, S1P induces vasodilation through the receptors S1P 1 and S1P 3 on endothelial cells, via activation of endothelial nitric oxide synthase (eNOS) and NO 8, 9 . At higher concentrations, S1P causes vasoconstriction through S1P 2 and S1P 3 activation on vascular smooth muscle cells (VSMCs) 10, 11 .
The endothelium is not only a target of S1P action but also an important source of plasma S1P 12 ; red blood cells are the major source [12] [13] [14] . Stimulated by blood flow, endothelial-derived S1P is transported out of the cell through the spinster-2 transporter 15 ; S1P activates S1P 1 on the cell surface in an autocrine fashion to induce barrier-protective effects 16 and control vascular tone. Moreover, a recent study reported that S1P 1 is required for eNOS-activation in response to shear stress 17 . These findings suggest that S1P levels within the vascular wall must be tightly controlled to maintain vascular homeostasis. How S1P production within the vascular wall is regulated and the roles of S1P in physiological and hypertensive conditions are still unknown.
Sphingolipids are produced by the de novo biosynthetic pathway in the endoplasmic reticulum (ER). The rate-limiting enzyme, serine palmitoyltransferase (SPT), catalyzes the condensation of serine and palmitoyl-coenzyme A 18, 19 . Because sphingolipids are involved in many pathophysiological processes, the expression and regulation of SPT has attracted much attention. A recently discovered major regulatory system for SPT involves ORMDL proteins 20, 21 , which have been suggested to be involved in childhood asthma on the basis of genome-wide association studies 22 . Here we identify Nogo-B, a membrane protein of the ER and part of the reticulon-4 (Rtn4) protein family, as a key negative regulator of de novo sphingolipid biosynthesis and reveal the importance of local sphingolipid homeostasis in preserving endothelial function and blood pressure.
RESULTS

Nogo-B regulates blood pressure through an eNOS pathway
Nogo-B belongs to the Rtn4 family of proteins, which comprises three major splice isoforms: Nogo-A and Nogo-C are abundantly expressed in the central nervous system, and Nogo-C 23, 24 is also found in skeletal muscle; Nogo-B is expressed highly but not exclusively in endothelial cells and VSMCs of blood vessels, including mesenteric arteries 25 (Fig. 1a) . Mice lacking the Nogo-A and Nogo-B isoforms (hereafter referred to as Nogo-A/B-deficient mice) 24 , were markedly hypotensive compared to wild-type (WT) control mice (Fig. 1b) , with no significant increase in heart rate. Consistent with their lower blood pressure, the thickness/radius ratio of the mesenteric arteries of Nogo-A/B-deficient mice was significantly reduced as compared with WT mice (Fig. 1b) . To assess the role of Nogo-B in VSMC function, we evaluated vasoconstriction in the mesenteric arteries of WT and Nogo-A/B-deficient mice in response to increasing concentrations of the adrenergic α 1 receptor agonist phenylephrine (PE), the thromboxane A 2 receptor agonist U-46619 and S1P (S1P 2 and S1P 3 receptor ligand). We found no differences between the two groups of mice in the vasoconstrictive responses of the mesenteric arteries (Supplementary Fig. 1a-c and Supplementary Data 1) , suggesting that hypotension in Nogo-A/B-deficient mice cannot be ascribed to an impaired contractility of resistance vessels. Accordingly, we focused on the role of Nogo-B in the endothelium.
Given the important role of NO as an endogenous endothelialderived vasodilator, we assessed the activation of eNOS. Nogo-A/Bdeficient aortas showed a marked increase of eNOS phosphorylated at Ser1176 (p-Ser1176-eNOS) as compared to WT aortas, as assessed by western blot and en face immunofluorescence staining (Fig. 1c,d ), whereas total eNOS ( Fig. 1c and Supplementary Fig. 1d ) and neuronal NOS (nNOS) (Supplementary Fig. 1e) Numbers represent the p-Ser1176-eNOS/eNOS ratio as determined by densitometric analysis. β-actin was used as a loading control. (d) En face staining of WT and Nogo-A/B-deficient aortas for eNOS, p-Ser1176-eNOS and vascular endothelial (VE)-cadherin. (e) Top, plasma levels of nitrite (NOx) in WT and Nogo-A/B-deficient mice (n = 9 mice per group); bottom, basal (Bas) and A23187-stimulated cGMP concentrations in aortas from WT and Nogo-A/B-deficient mice (n = 5 mice per group). Error bars, mean ± s.e.m. *P < 0.05; **P < 0.01, unpaired t-test (top) or one-way ANOVA (bottom). (f) Left, l-NAME-induced decrease in luminal diameter versus baseline in mesenteric arteries from WT (n = 9) and Nogo-A/B-deficient (n = 7) mice. Right, Ach concentration-response curves with or without l-NAME treatment in mesenteric arteries from WT (n = 8) and Nogo-A/B-deficient (n = 5) mice. Error bars, mean ± s.e.m. **P < 0.01; ***P < 0.001, unpaired t-test (left) or two-way ANOVA followed by Bonferroni's post hoc test (right). (g) Ach concentration-response curves in the presence or absence of indomethacin (indom) in mesenteric arteries from WT (n = 11) and Nogo-A/B-deficient (n = 6) mice. Error bars, mean ± s.e.m. ***P < 0.001, two-way ANOVA. (h) Ach concentration-response curves after incubation with indomethacin and l-NAME in mesenteric arteries from WT and Nogo-A/B deficient mice (n = 5 per group). (i) Left, flow-induced vasodilation without and with l-NAME treatment in mesenteric arteries from WT (n = 6) and Nogo-A/B-deficient (n = 7) mice. Right, myogenic tone without and with l-NAME treatment in mesenteric arteries from WT (n = 5) and Nogo-A/B-deficient (n = 8) mice. P, pressure. Error bars, mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001, two-way ANOVA (right) followed by Bonferroni's post hoc test (left). (j) Left, l-NAME-induced decrease, compared to baseline, in luminal diameter in carotid arteries from WT and Nogo-A/B-deficient mice (n = 6 mice per group); middle, Ach concentration-response curves without or with l-NAME (n = 6 per group); right, flow-induced vasodilation without or with l-NAME (n = 6 per group). Error bars, mean ± s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001, unpaired t-test (left) or two-way ANOVA followed by Bonferroni's post hoc test (middle and right). These findings were supported by higher plasma levels of nitrites (a breakdown product of NO) and a robust increase in basal and stimulated cyclic guanosine monophosphate (cGMP) levels in Nogo-A/Bdeficient aortas as compared to WT (Fig. 1e) . To confirm these data, we evaluated basal and acetylcholine (Ach)-stimulated eNOS-derived NO in mesenteric arteries mounted in a pressure myograph. We used l-NG-nitroarginine methyl ester (l-NAME) and indomethacin as pharmacological inhibitors of eNOS and cyclooxygenase, respectively, to dissect the role of NO, prostacyclin and endothelium-derived hyperpolarizing factor (EDHF) in Ach-induced vasodilation. Basal and stimulated NO production were markedly increased in mesenteric arteries from Nogo-A/B-deficient mice as compared to controls (Fig. 1f) . In contrast, the contribution of prostacyclin to vasodilation was significantly smaller in Nogo-A/B-deficient than in WT mesenteric arteries (Fig. 1g) . EDHF had an equal role in Nogo-A/Bdeficient and WT mesenteric arteries, leaving the net response to Ach unchanged (Fig. 1h) . These results were not surprising, given the compensatory cross-talk between the NO and cyclooxygenase (COX) pathways 26 . These data suggest that endothelial Nogo-B negatively regulates eNOS-derived NO production. Flow-induced dilation and pressure-induced constriction (myogenic tone) are fundamental mechanisms controlling vascular tone, with flow-induced dilation opposing myogenic tone 27, 28 . NO is the major mediator of flow-induced vasorelaxation. In Nogo-A/Bdeficient mesenteric arteries, vasodilation in response to a stepwise increase in flow was significantly enhanced compared to WT arteries (Fig. 1i) . l-NAME treatment blunted flow-induced vasorelaxation in both groups. Conversely, the development of myogenic tone induced by a stepwise increase in pressure was substantially reduced in WT mesenteric arteries in the absence of Nogo-B; l-NAME treatment potentiated the myogenic response to pressure equally in the two groups (Fig. 1i) . Loss of Nogo-B led to hyperactivation of eNOS and increased flow-induced vasodilation in carotid arteries (Fig. 1j) . Together, these findings suggest that endothelial Nogo-B has an important role in the regulation of vessel tone via the endothelial NO pathway, such that loss of Nogo-B alters systemic blood pressure. , n = 7 and n = 7 replicates, respectively, derived from 3 independent experiments). Top, western blotting for Nogo-B in HUVECs (left) and in MLECs (right). (i,j) SPT activity in lung microsomes from WT and Nogo-A/B-deficient mice (n = 11 replicates derived from 6 mice per group) (i) and in HUVECs transfected with Nogo-B receptor siRNA (si-NgBR) or control siRNA (si-CTR) and cultured for 72 h (n = 9 replicates derived from 3 independent experiments) (j). The western blot in j shows levels of NgBR and HSP90 in HUVECs. Data are expressed as mean ± s.e.m. *P < 0.05; **P < 0.01 compared to WT; ## P < 0.01 compared to control (si-CTR) HUVECs (unpaired t-test) (a-d,h-j).
npg Nogo-B negatively regulates sphingolipid synthesis through SPT Considering the subcellular localization of Nogo-B and eNOS in the tubular ER and the Golgi, respectively, we reasoned that a direct interaction between the two proteins is unlikely. Although it has been suggested that the Rtn4 protein regulates channels responsible for store-operated calcium entry in cultured fibroblasts 29 , the equivocal role of these channels in VSMC contractility and the normal contractile responses of Nogo-A/B-deficient mesenteric arteries in response to a variety of vasoconstrictors suggest that Nogo-B is unlikely to regulate calcium signaling in VSMCs. Moreover, Nogo-B does not alter triglyceride synthesis 29 . Given the importance of sphingolipids in controlling blood vessel function 8, 9, 17, 30 , we hypothesized that Nogo-B regulates sphingolipid homeostasis.
Quantification of sphingolipid levels by liquid chromatographytandem mass spectrometry (LC-MS/MS) showed a consistent increase (~30%) in total ceramide levels in the absence of Nogo-B in primary endothelial cells isolated from mouse lung (MLECs) but not in VSMCs (Fig. 2a, Supplementary Fig. 2a ,b and Supplementary Data 2). This may be due to differential contributions of the de novo sphingolipid pathway to sphingolipid levels in endothelial and smooth muscle cells (total ceramide levels were 1,417 ± 108 (s.e.m.) pmol mg −1 ml −1 in WT MLECs and 850 ± 46 (s.e.m.) pmol mg −1 ml −1 in WT VSMCs; Fig. 2a and Supplementary Fig. 2a) . Quantification of sphingolipid species in endothelial cells showed that only specific ceramide species, including cer-C18, cer-C20 and cer-C22, were significantly increased in the absence of Nogo-B (Fig. 2b) , whereas the levels of cer-C16, cer-C24 and -test (a,g,j) , one-way ANOVA (b,c) or two-way ANOVA followed by Bonferroni's post hoc test (e,f,h,i).
npg cer-C24:1 (the most abundant ceramide species, which are involved in apoptosis 31 and survival signaling 32 ), were unchanged (Fig. 2b) . Notably, the levels of sphingosine, a breakdown product of ceramide and a direct precursor of S1P, were markedly higher in Nogo-A/Bdeficient MLECs than in WT MLECs (~50%; Fig. 2b ). Endothelial cells actively produce and secrete S1P 12 , and intracellular S1P levels are tightly controlled by sphingosine kinases and degrading enzymes such as S1P phosphatases and lyase 33 . In the presence of phosphatase inhibitors 12 , S1P levels in the culture medium were significantly higher in Nogo-A/B-deficient cells than in WT cells (Fig. 2c) . Myriocin, a specific inhibitor of SPT, suppressed S1P production in both groups (Fig. 2c) , suggesting that the de novo pathway is responsible for the upregulation of S1P production in the absence of Nogo-B. Significantly higher plasma levels of S1P in Nogo-A/B-deficient mice than in WT mice corroborated these in vitro findings (Fig. 2d) .
Next, we studied the interaction between Nogo-B and SPT, the rate-limiting enzyme of the de novo sphingolipid biosynthetic pathway. First, we expressed HA-tagged Nogo-B and SPTLC1, the transmembrane subunit of SPT, in HEK293T cells and found that SPTLC1 coimmunoprecipitated with Nogo-B (Fig. 2e) . ORMDL 20 , a known SPT-interacting protein, coimmunoprecipitated with the Nogo-B-SPT complex, but calnexin did not, indicating that the interaction between SPTLC1 and Nogo-B was specific. Nogo-B was also immunoprecipitated from mouse lung lysate (Fig. 2f) , indicating an in vivo interaction between Nogo-B and SPTLC1. Moreover, the two proteins colocalized in the tubular ER of COS7 cells transfected with SPTLC1 and HA-tagged Nogo-B (Fig. 2g) . To define the biological function of the Nogo-B-SPT interaction, we measured [ 3 H]serine incorporation into sphinganine (a downstream product of the SPT reaction) in endothelial cells and separated the extracted sphingolipids by thin layer chromatography (TLC) to assess the enzymatic activity of SPT (Supplementary Fig. 2c-e) . Genetic deficiency of Nogo-B (in MLECs) or small interfering RNA (siRNA)-mediated knockdown of Nogo-B (in human umbilical vein endothelial cells (HUVECs)) led to an increase in SPT activity (Fig. 2h) , which was restored to WT levels by lentiviral-mediated expression of Nogo-B in Nogo-A/B-deficient MLECs (Fig. 2h) . To exclude possible effects on [ 3 H]serine uptake, we assayed SPT activity in microsomes isolated from WT and Nogo-A/B-deficient lungs and confirmed that SPT activity was enhanced in the absence of Nogo-A and Nogo-B (Fig. 2i) . Western blot analysis of WT and Nogo-A/B-deficient microsomes and soluble fractions showed no difference between the two groups in SPTLC1 and calnexin distribution ( Supplementary  Fig. 2f ). The Nogo receptor NgBR has been proposed to mediate effects of plasma membrane-localized Nogo-B (<5% of total Nogo-A/B-deficient arteries) and (d) effects on Ach-induced vasodilation using l-NAME (left, n = 6 per group), indomethacin (middle, n = 8 per group) and l-NAME plus indomethacin (right, n = 8 WT and n = 6 Nogo-A/B-deficient arteries). (e) Plasma levels of nitrites (NOx) in WT and Nogo-A/Bdeficient mice treated with AngII or vehicle (n = 4 per group). (f-h) Mesenteric arteries from WT and Nogo-A/B-deficient mice treated with AngII or vehicle and assessed for (f) flow-induced vasodilation (n = 5 per group), (g) vasoconstriction in response to PE (n = 9 WT and n = 6 Nogo-A/B-deficient arteries) and (h) myogenic tone (n = 8 per group). (i) WT and Nogo-A/B-deficient mice treated with SEW2871 (3 mg/kg, i.p.) after 4 weeks of chronic infusion of AngII. n = 7 per group. Data are expressed as the mean ± s.e.m.; *P < 0.05; **P < 0.01; ***P < 0.001 compared to WT (a,c-i); # P < 0.05 compared to WT control (e). Statistical significance was determined by two-way ANOVA followed by Bonferroni's post hoc test (a,c,d ,f-i) or one-way ANOVA (e).
npg Nogo-B) on vascular function 25 . Notably, siRNA-mediated knockdown of NgBR did not alter the activity of SPT in HUVECs (Fig. 2j) , suggesting that the intracellular regulation of de novo sphingolipid biosynthesis by Nogo-B is not mediated by NgBR.
Nogo-B binds SPT to regulate blood pressure through S1P-S1P 1 axis To confirm the causal role of sphingolipid upregulation in the hypotension observed in Nogo-A/B-deficient mice, we inhibited SPT activity in vivo with myriocin 34 and measured physiological outcomes. In Nogo-A/B-deficient mice, a single dose of myriocin normalized blood pressure (Fig. 3a) , NO plasma levels (Fig. 3b) and basal tone in mesenteric arteries ex vivo (Fig. 3c) , whereas myriocin treatment did not affect the contributions of NO, prostacyclin and EDHF to Ach-induced vasodilation (Fig. 3d, Supplementary Fig. 3a  and Supplementary Data 3) . Further, myriocin abolished the difference in flow-induced dilation between WT and Nogo-A/B-deficient mesenteric arteries and increased myogenic tone to the same degree in both groups (Fig. 3e) . Myriocin did not alter the response of arteries to PE, but increased basal tone in both groups, probably owing to diminished basal eNOS activation (Fig. 3e) . These results indicate that upregulation of the de novo sphingolipid biosynthetic pathway is the major mechanism responsible for the decrease in vascular and myogenic tone (right; n = 6 Nogo-A/B f/f , n = 11 EC-Nogo-A/B-deficient and n = 6 SMC-Nogo-A/B-deficient mice per control group, and n = 6 Nogo-A/B f/f , n = 11 EC-Nogo-A/B-deficient and n = 9 SMC-Nogo-A/B-deficient mice per AngII group). Data are expressed as mean ± s.e.m.; **P < 0.01; ***P < 0.001 compared to WT (a-i); ## P < 0.01, AngII vs. control; † P < 0.05, AngII vs. control (h); ### P < 0.001, EC-Nogo-A/B-deficient vs. Nogo-A/B f/f (i). Statistical significance was determined by one-way ANOVA (a-c,h) or two-way ANOVA followed by Bonferroni's post hoc test (d-g,i) . S1P produced in the endothelium is transported out of the cell to activate the S1P 1 -eNOS pathway 12, 30 . eNOS-derived NO is a major effector of S1P-mediated S1P 1 activation (Supplementary Fig. 3b) . To investigate more directly the role of autocrine S1P-S1P 1 -eNOS signaling in endothelial cells in the regulation of vascular tone, we used W146, a known antagonist of S1P 1 (half-maximal inhibitory concentration (IC 50 ) of 70 nM) (Fig. 3f) . In WT mesenteric arteries, W146 treatment reduced basal eNOS activation and increased basal tone and vasoconstriction in response to PE (Supplementary Fig. 3c-e) , whereas it did not affect the contributions of prostacyclin, NO and EDHF to Ach-induced vasodilation (Supplementary Fig. 3f,g) . Notably, at a concentration of 1 µM, W146 blunted flow-mediated vasodilation and significantly increased myogenic tone in WT mesenteric arteries (Fig. 3f) . The importance of S1P 1 to the flowmediated response has previously been reported for endothelial cells in culture 12 . Our results with W146 demonstrate the direct role of S1P 1 receptors in the response to blood flow in resistance vessels and implicate an augmented myogenic tone as a counteracting response to the loss of flow-induced vasodilation.
On the basis of these findings, we hypothesized that an endothelial S1P-S1P 1 -eNOS autocrine loop is upregulated in Nogo-A/B-deficient mesenteric arteries and that this upregulation accounts for the increase in flow-induced dilation and NO release. In this scenario, we would expect high activation of S1P 1 receptors in Nogo-A/B-deficient mesenteric arteries under baseline conditions. Indeed, the increase of vascular tone was greater in Nogo-A/B-deficient than in WT mesenteric arteries after W146 treatment (Fig. 3g) , indicating a gain of S1P 1 signaling in the absence of Nogo-B. Notably, partial inhibition of S1P 1 by W146 normalized the flow response and myogenic tone of Nogo-A/B-deficient mesenteric arteries (Fig. 3h) . Upregulation of an S1P-S1P 1 -eNOS autocrine loop in absence of Nogo-A and Nogo-B was further corroborated by the observation that S1P-induced vasodilation was markedly reduced in Nogo-A/B-deficient mesenteric arteries as compared to WT (Fig. 3i) . Moreover, myriocin treatment increased the sensitivity of WT and Nogo-A/B-deficient mesenteric arteries to S1P to the same degree (Fig. 3i) , and S1P 1 expression was similar between the two groups (Fig. 3j) . Taken together, these findings suggest a protective role of S1P signaling and indicate that hyperactivation of endothelial S1P-S1P 1 -eNOS autocrine signaling accounts for the reduced vascular tone observed in the absence of Nogo-B.
Nogo-B mediates vascular dysfunction in hypertension
To assess the importance of Nogo-B in pathological conditions, we employed the angiotensin II (AngII)-induced model of hypertension, which recapitulates features of human hypertension, including vascular dysfunction [35] [36] [37] . Chronic infusion of AngII produced robust and sustained hypertension in WT mice, whereas it induced only a mild increase in blood pressure in Nogo-A/B-deficient mice (Fig. 4a) . Notably, myriocin administration raised the blood pressure of AngII-treated Nogo-A/B-deficient mice to that of AngII-treated WT mice (Fig. 4a) .
Immunofluorescence staining of mesenteric arteries revealed that Nogo-B was expressed in both endothelial cells and VSMCs in vehicle-treated WT mice and that Nogo-B levels were much lower in VSMCs but unchanged in endothelial cells in the mesenteric arteries of hypertensive (AngII-treated WT) mice (Fig. 4b) . These findings suggest that Nogo-B exerts pro-hypertensive effects in endothelial cells rather than in VSMCs.
Consistent with these in vivo findings, mesenteric arteries from AngII-treated Nogo-A/B-deficient mice were protected from endothelial dysfunction, showing preserved vasorelaxation in response to Ach and preserved NO production, with no difference in the contribution of prostacyclin and EDHF to Ach-induced vasodilation (Fig. 4c-e) , and a sustained vasodilatory response to blood flow (Fig. 4f) . Mesenteric arteries from WT mice showed greater myogenic tone and increased vasoconstriction in response to PE than did those from Nogo-A/B-deficient mice (Fig. 4g,h) .
Finally, to directly assess the protective role of S1P 1 signaling in hypertension, we injected AngII-treated WT and Nogo-A/B-deficient mice with SEW2871, a selective agonist of S1P 1 . SEW2871 administration Figure 6 Endothelial Nogo-B is a critical mediator of hypertension and vascular dysfunction through negative regulation of sphingolipid de novo biosynthesis. Endothelial-derived S1P has a crucial function in flow-mediated vasodilation through an autocrine S1P 1 -eNOS signaling axis. S1P is transported out of endothelial cells, where it activates S1P 1 -eNOS pathway in an autocrine fashion, leading to NO production and blood pressure regulation. Left, in the absence of Nogo-B, SPT activity is enhanced and endothelial cells produce increased amounts of S1P, resulting in increased flow-mediated vasodilation and decreased basal tone. Myriocin, a specific inhibitor of SPT, and W146, an S1P 1 antagonist, reinstate the normal response to blood flow and pressure in Nogo-A/B-deficient resistance arteries. SEW2871, an agonist of S1P 1 , lowers blood pressure in hypertensive mice. Right, the lack of Nogo-B in smooth muscle cells leads to an increase in sphingolipid biosynthesis and ceramide levels, resulting in decreased myogenic tone. EC, endothelial cell.
npg led to a marked hypotensive response in WT but not Nogo-A/Bdeficient mice; the blood pressure of AngII-treated Nogo-A/Bdeficient mice was close to normal values (Fig. 4i) . These data demonstrate that in a hypertensive model, Nogo-B negatively regulates the de novo pathway of sphingolipid biosynthesis in the vasculature, leading to endothelial dysfunction and higher blood pressure.
Endothelial Nogo-B promotes vascular dysfunction and hypertension To dissect the roles of Nogo-B in endothelial and smooth muscle cells, we generated mice lacking Nogo-A and Nogo-B specifically in endothelial cells or in smooth muscle cells. We first generated mice with a loxPflanked allele of the gene encoding Nogo-A and Nogo-B (Nogo-A/B f/f ). We then bred these mice to mice expressing Cre recombinase specifically in endothelial or smooth muscle cells to generate endothelial cell ( As reported by other groups 25, 38 , Nogo-A is not detectable in endothelial cells; thus, the phenotype observed in EC-Nogo-A/B-deficient mice can be ascribed to the specific loss of Nogo-B.
The lack of Nogo-B in endothelial cells and, to a lesser extent, in smooth muscle cells, led to a marked reduction in baseline blood pressure (Fig. 5a) , recapitulating the effects observed in systemic Nogo-A/B-deficient mice and suggesting that Nogo-B acts predominantly in endothelial cells to regulate systemic blood pressure. We observed increased plasma levels of NO and increased basal and Achstimulated production of NO in mesenteric arteries specifically in EC-Nogo-A/B-deficient mice, whereas myogenic tone (but not PEinduced vasoconstriction) (Supplementary Fig. 4h ) was significantly reduced in mesenteric arteries from SMC-Nogo-A/B-deficient mice (Fig. 5b-e) . These results indicate that endothelial Nogo-B affects flow-induced vasodilation through the S1P-S1P 1 -eNOS axis, whereas smooth muscle Nogo-B regulates myogenic tone. EC-Nogo-A/Bdeficient mice were protected from AngII-induced hypertension and endothelial dysfunction, with preserved production of NO under baseline and Ach-stimulated conditions, and had a preserved vasodilatory response to flow (Fig. 5f-i) . AngII-treated SMC-Nogo-A/Bdeficient mice developed a milder hypertension than did Nogo-A/B f/f control mice, probably because of a reduced myogenic tone; however, SMC-Nogo-A/B-deficient mice showed endothelial dysfunction and impaired flow-mediated vasodilation, similarly to control Nogo-A/B f/f mice ( Fig. 5f-i) . Ceramide-activated serine-threonine phosphatases (CAPPs) such as phosphatase 1 (PP1) and phosphatase 2A (PP2A), which have a defined role in smooth muscle cell contractility 39 , have been found to interact with ceramide 40 . Increased levels of cer-C18, cer-C20 and cer-C22 in smooth muscle cells of SMC-Nogo-A/Bdeficient mice may therefore be responsible for the reduced myogenic tone observed in these mice. Together, these findings suggest that Nogo-B, acting predominantly in endothelial cells, contributes to vascular dysfunction and hypertension (Fig. 6) .
DISCUSSION
Dysfunction of the endothelium is associated with hypertensive cardiovascular disease and probably precedes its development 3, 41 . Recently, bioactive sphingolipids, and S1P in particular, have been shown to regulate important aspects of cardiovascular pathophysiology, including angiogenesis, vascular tone and endothelial barrier integrity [42] [43] [44] . Although altered sphingolipid signaling has been implicated in endothelial dysfunction and cardiovascular disease 42, 45 , the specific molecular mechanisms involved are still poorly understood.
Our study identifies Nogo-B as a negative regulator of the de novo pathway of sphingolipid biosynthesis, independently of NgBR 46 . We found that Nogo-B binds to and inhibits the activity of SPT, the ratelimiting enzyme of the pathway. Thus, loss of a Nogo-B-mediated brake on SPT leads to an increase in locally produced sphingolipids and S1P in the endothelium, exerting vasculoprotective effects.
Indeed, S1P is a potent activator of eNOS through S1P 1 and S1P 3 , and many of the beneficial effects of S1P on the vasculature are mediated by NO, including cell survival, proliferation and migration 47, 48 . Our data on the S1P 1 antagonist W146 corroborate the role of S1P 1 in blood flow-induced dilation in resistance vessels and provide direct evidence of the importance of endothelial-derived S1P in controlling vascular response to flow through an autocrine-paracrine loop involving S1P 1 -eNOS signaling.
To date, the impact of S1P receptor modulators on cardiovascular pathophysiology remains largely unexplored. Here, we reveal antihypertensive effects of S1P 1 signaling, identifying a potential therapeutic target for the treatment of this pathological condition. Recently S1P receptor modulation has become an attractive pharmacological target [49] [50] [51] . Our findings suggest that potential cardiovascular effects should be a consideration in the development of such agents.
Although much attention has been devoted to the sphingolipid recycling pathway and the role of sphingomyelinase in cardiovascular disease 52 , relatively little attention has been paid to the function of the de novo pathway in this context. Our studies reveal a protective function of the de novo pathway within the vasculature in the pathogenesis of hypertension. The production of endothelial S1P is strongly sustained by the de novo pathway; indeed, we found that the SPT inhibitor myriocin reduced S1P levels in the culture medium of endothelial cells by ~50% after only 4 h of incubation, and a single dose of myriocin normalized the blood pressure of Nogo-A/B-deficient mice and restored blood flow-induced vasodilation, myogenic tone and NO production of mesenteric arteries. Our pharmacological data using the S1P 1 antagonist W146 and an SPT inhibitor myriocin indicate the importance of local S1P-S1P 1 -eNOS signaling in the regulation of vascular tone in both normal physiology and hypertension. Moreover, the ability of the selective S1P 1 antagonist SEW2871 to normalize blood pressure in hypertensive mice reveals the critical role of S1P 1 -mediated signaling in hypertension.
Genome-wide association studies have identified a strong association between the ORMDL locus and the incidence of childhood asthma 22 , and Orm proteins in yeast (ORMDL proteins in human) have recently been identified as negative regulators of SPT 20 . We found that ORMDL coimmunoprecipitated with Nogo-B and SPTLC1, suggesting that these proteins are part of the same complex. Moreover, Nogo-A and Nogo-B deficiency led to an increase in microsomal SPT activity in the lung, suggesting that Nogo-B is a regulatory factor of SPT.
Despite expression of Nogo-B in both endothelial and smooth muscle cells, Nogo-B has a selective impact on sphingolipid synthesis in endothelial cells, particularly with respect to the steady-state levels of cer-C18, cer-C20 and cer-C22. This selective effect may be due to differential contributions of the de novo pathway of sphingolipid biosynthesis in endothelial cells and VSMCs, differential regulation of sphingolipid biosynthesis depending on cell type and pathological conditions, or cell type-specific functioning of Nogo-B.
Our findings in resistance arteries from systemic and EC-Nogo-A/Bdeficient mice indicate the important role of Nogo-B in vascular tone regulation by control of local sphingolipid production. In a recent study, npg a specific extracellular domain of Nogo-A was proposed to activate S1P 2 in the brain 53 . The S1P 2 receptor is also expressed in VSMCs 11 ; however, Nogo-A is undetectable in the mouse aorta and femoral artery 25 , excluding the possibility that the vascular phenotype of Nogo-A/B-deficient mesenteric and carotid arteries is due to lack of Nogo-A-mediated signaling in the vasculature. Although our data in Nogo-A/B-deficient mice do not rule out a possible contribution of Nogo-A, which is enriched in the brain, in the control of blood pressure, the hypotension of EC-Nogo-A/B-deficient mice and their resistance to hypertension and vascular dysfunction can be attributed to endothelial-expressed Nogo-B.
The finding that Nogo-B regulates sphingolipid signaling provides a framework for investigating whether alterations of Nogo activity and sphingolipid metabolism contribute to other pathological conditions that have been reported in mice lacking Nogo-B, including vascular injury 25 , asthma 54 and liver fibrosis 55 and inflammation 56 . The observation that Nogo-B controls sphingolipid metabolism strongly suggests that dysregulation of this signaling pathway may have a causative role in the pathogenesis of hypertension and endothelial dysfunction leading to cardiovascular disease. Most notably, the identification of regulatory mechanisms for endothelial sphingolipid production may allow for targeted pharmacological intervention of these pathways in cardiovascular disease.
METHODS
Methods and any associated references are available in the online version of the paper. 
